HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues.

MLA

Lockbaum, Gordon J., et al. “HIV-1 Protease Inhibitors with a P1 Phosphonate Modification Maintain Potency against Drug-Resistant Variants by Increased Interactions with Flap Residues.” European Journal of Medicinal Chemistry, vol. 257, Sept. 2023, p. 115501. EBSCOhost, https://doi.org/10.1016/j.ejmech.2023.115501.

APA

Lockbaum, G. J., Rusere, L. N., Henes, M., Kosovrasti, K., Rao, D. N., Spielvogel, E., Lee, S.-K., Nalivaika, E. A., Swanstrom, R., Yilmaz, N. K., Schiffer, C. A., & Ali, A. (2023). HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues. European Journal of Medicinal Chemistry, 257, 115501. https://doi.org/10.1016/j.ejmech.2023.115501

Chicago

Lockbaum, Gordon J, Linah N Rusere, Mina Henes, Klajdi Kosovrasti, Desaboini Nageswara Rao, Ean Spielvogel, Sook-Kyung Lee, et al. 2023. “HIV-1 Protease Inhibitors with a P1 Phosphonate Modification Maintain Potency against Drug-Resistant Variants by Increased Interactions with Flap Residues.” European Journal of Medicinal Chemistry 257 (September): 115501. doi:10.1016/j.ejmech.2023.115501.